With the 2022 Cell & Gene Meeting on the Mesa (#CGMesa22) underway, here’s a look at some notable recent developments in cell and gene therapy featured in the bimonthly newsletter, Cell and Gene Therapy Business Outlook. Myrtelle, a clinical-stage gene therapy company based in Wakefield, MA, and Forge Biologics, a gene therapy contract development and […]
There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Kite Pharma, a Gilead Company based in Santa Monica, CA, has announced that the European Commission (EC) has granted approval for its chimeric antigen receptor (CAR) T cell therapy Tecartus […]
There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Prescient Therapeutics, a clinical stage oncology company based in Melbourne, Australia, has signed a five-year manufacturing agreement with Q-Gen Cell Therapeutics, a specialist cell therapy manufacturer based at the QIMR […]
There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. The U.S. FDA has lifted clinical holds on two Phase III clinical studies evaluating gene therapies being developed by Pfizer, based in New York, NY. On April 28th, Pfizer announced […]
Over 54 BN across funding mechanisms. Private, VC, SPAC and and IPO Over 20Billion The enormous amount of funding presages confidence in discoveries of future marketable products as well as platforms in cell and gene therapy. With an aggressive third quarter 2021 for funding, it is worthwhile to total and assess where we are. In […]
Email Us: Customer Service
Phone (US): 703-778-3080
Fax: 703-778-3081
